GlassScriptPhysician profile
Dexter T Estrada
NPI 1013032713
$8,781.88
in general payments reported to CMS, 2019-2025
54 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $801 · 2021: $1,384 · 2022: $1,389 · 2023: $1,288 · 2024: $1,601 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,461 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,460.63 |
| Education | $295.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,231.92 | 2019-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $839.43 | 2019-2025 | Jemperli, Zejula, Ojjaara |
| Celgene Corporation | $805.37 | 2019-2025 | Opdualag, Pomalyst, Reblozyl |
| Novartis Pharmaceuticals Corporation | $531.97 | 2019-2025 | |
| Exelixis INC. | $403.07 | 2019-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $360.32 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Abbvie INC. | $312.08 | 2020-2025 | |
| Daiichi Sankyo INC. | $286.06 | 2020-2025 | Enhertu, Injectafer, Vanflyta |
| Kite Pharma, INC. | $253.47 | 2019-2023 | Yescarta |
| Aveo Pharmaceuticals, INC. | $252.94 | 2022-2023 | Fotivda |
| Alexion Pharmaceuticals, INC. | $224.85 | 2019-2023 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $215.66 | 2020-2025 | Onivyde, Tazverik |
| Pharmacyclics LLC, An Abbvie Company | $198.45 | 2021-2023 | Epkinly, Imbruvica |
| Gilead Sciences, INC. | $185.64 | 2019-2025 | Trodelvy |
| Sirtex Medical INC | $174.50 | 2019-2024 | Sir-Spheres Microspheres |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dexter Estrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.